Core Viewpoint - Anke Biopharma announced the presentation of clinical research data for its innovative drug HuA21 at the ESMO annual meeting, highlighting its efficacy and safety in treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma [1] Group 1: Company Developments - Anke Biopharma will present the latest research findings on HuA21, a recombinant anti-HER2 humanized monoclonal antibody injection, at the ESMO annual meeting in Berlin from October 17 to 21, 2025 [1] - The clinical study data for HuA21 in combination with trastuzumab and chemotherapy further confirms its good anti-tumor activity and tolerable safety profile [1] Group 2: Industry Implications - The results from the clinical research provide support for the Phase III clinical trial, potentially accelerating the drug development process [1]